Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 3 5 M.
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 3 5 M.
AMINOSYN 8.5% W/ELECTROLYTES vs AMINOSYN II 3.5% M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition. It provides essential and non-essential amino acids necessary for protein synthesis, tissue repair, and maintenance of nitrogen balance. Electrolytes are included to maintain acid-base balance and normal cellular function.
Provides essential and nonessential amino acids for protein synthesis, serving as substrates for anabolic processes in parenteral nutrition.
Intravenous infusion: 500 mL to 1000 mL of 8.5% solution (42.5-85 g amino acids) once daily, infused at a rate not exceeding 100 mL/hour.
Intravenous infusion of 1.2 to 2.2 g amino acids per kg per day, adjusted to meet metabolic and nutritional requirements. Typical adult dose: initial infusion rate of 50 mL/hour, increasing to 125 mL/hour (4.4 g amino acids per hour) based on tolerance. Not for direct peripheral administration without supplementation of electrolytes and/or dextrose.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for essential amino acids and 0.5-2 hours for non-essential amino acids, reflecting rapid distribution and metabolism in healthy adults. In renal or hepatic impairment, half-life may be prolonged.
The terminal elimination half-life of amino acids from the infusion mixture is not uniformly defined; however, individual amino acids have half-lives ranging from 10 to 30 minutes. For the mixture, the effective half-life is clinically considered to be approximately 1-2 hours, reflecting rapid metabolic clearance. In renal impairment, the half-life may be prolonged due to reduced urea clearance.
Amino acids are primarily eliminated via metabolism (deamination, transamination) and incorporation into proteins. Unmetabolized amino acids are excreted renally (approximately 5-10% of administered dose, depending on renal function and infusion rate). Fecal and biliary excretion are negligible (<1%).
Aminosyn II 3.5% M is a crystalline amino acid solution. Amino acids are primarily eliminated by metabolic utilization for protein synthesis and energy production. Excess amino acids undergo deamination, with nitrogen excreted as urea in urine via renal route. Fecal and biliary excretion are negligible. Approximately 80-90% of infused nitrogen is recovered as urea in urine in patients with normal renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution